华东医药：目前公司暂无港股上市计划

Core Viewpoint - The company has no current plans for a Hong Kong stock listing and emphasizes its commitment to open collaboration while strengthening its own R&D efforts [1][3]. Group 1 - The company stated that it is actively exploring business development (BD) opportunities for innovative drug pipelines in collaboration with global peers [1]. - The management clarified that any future cooperation agreements will be disclosed in accordance with information disclosure regulations [1]. - There is a perception in the market that the company is primarily a generic and industrial pharmaceutical firm, and it is seeking to change this image through actual actions [3].